Trial Profile
Bumetanide has a more favourable effect on insulin resistance than furosemide in patients with heart failure - a pilot study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2015
Price :
$35
*
At a glance
- Drugs Bumetanide (Primary) ; Furosemide (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 13 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Aug 2008 The expected completion date for this trial is now 1 Dec 2010.
- 23 Oct 2006 New trial record.